Mark Litton
2018 - Nivalis Therapeutics
In 2018, Mark Litton earned a total compensation of $985K as Former President and Chief Operating Officer at Nivalis Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $48,700 |
|---|---|
| Option Awards | $768,812 |
| Salary | $166,365 |
| Other | $1,100 |
| Total | $984,977 |
Litton received $768.8K in option awards, accounting for 78% of the total pay in 2018.
Litton also received $48.7K in non-equity incentive plan, $166.4K in salary and $1.1K in other compensation.
Rankings
In 2018, Mark Litton's compensation ranked 9,272nd out of 14,244 executives tracked by ExecPay. In other words, Litton earned more than 34.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,272 out of 14,244 | 35th |
Division Manufacturing | 3,707 out of 5,765 | 36th |
Major group Chemicals And Allied Products | 1,394 out of 2,128 | 35th |
Industry group Drugs | 1,172 out of 1,817 | 36th |
Industry Pharmaceutical Preparations | 909 out of 1,391 | 35th |
Source: SEC filing on April 24, 2019.
Litton's colleagues
We found three more compensation records of executives who worked with Mark Litton at Nivalis Therapeutics in 2018.